<DOC>
	<DOC>NCT00778609</DOC>
	<brief_summary>The aim of the present study is to investigate whether women taking a new combined oral contraceptive pill (SH T00658ID, estradiol valerate/dienogest) experience fewer hormone withdrawal-associated symptoms such as pelvic pain or headache during their monthly cycle compared to a commonly used contraceptive pill (Microgynon).</brief_summary>
	<brief_title>Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache</brief_title>
	<detailed_description />
	<mesh_term>Headache</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Ethinyl estradiol, levonorgestrel drug combination</mesh_term>
	<mesh_term>Ethinyl Estradiol-Norgestrel Combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Age between 18 and 50 years (inclusive) at visit 1, for smokers up to 35 years (inclusive) Otherwise healthy female subjects requesting contraception and currently using a levonorgestrel, gestodene or desogestrel containing oral contraceptive in a 21day regimen and suffering from at least moderate pelvic pain, headache or both defined by an average value of &gt;/= 35 mm for the 3 highest values on a visual analogue scale during cycle days 2228. Normal or clinically insignificant cervical smear not requiring further follow up (or a normal result obtained within the last 6 months before screening) Able to tolerate ibuprofen and willing to use only ibuprofen supplied for the study. Women with any contraindication for oral contraceptive use</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Combined Oral Contraceptives</keyword>
	<keyword>Pelvic Pain</keyword>
	<keyword>Headache</keyword>
</DOC>